Description
JZL 184 is a monoacylglycerol lipase (MAGL) inhibitor. JZL 184 shows anti-nociceptive effects and reduces inflammation when administered in vivo to Sprague-Dawley rats. JZL 184 treatment in tandem with the fatty acid amide hydrolase (FAAH) inhibitor PF-3845 decreases withdrawal symptoms in opioid-dependent rodent models. It also shows anti-depressive effects in the chronic unpredictable mild stress mouse model for depression. In hepatocellular carcinoma (HCC), MAGL is upregulated. JZL 184 has been shown to limit the effects of MAGL in HCC, inhibiting the proliferation and invasion of HCC cells, and increasing apoptosis